SLNO Quote, Financials, Valuation and Earnings

Marker Therapeutics, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -162.11%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.

Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 164.22%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 274.6%. Given that Marker Therapeutics, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Soleno Therapeutics, Inc..

Soleno Therapeutics, Inc. has a beta of -3.123, which suggesting that the stock is 412.272% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.371, suggesting its more volatile than the S&P 500 by 37.092%.

Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Soleno Therapeutics, Inc.'s net income of $26M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 20.98x versus 5.69x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -301.29%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Nektar Therapeutics's return on equity of -327.67%.

Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 164.22%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 208.35%. Given that Nektar Therapeutics has higher upside potential than Soleno Therapeutics, Inc., analysts believe Nektar Therapeutics is more attractive than Soleno Therapeutics, Inc..

Soleno Therapeutics, Inc. has a beta of -3.123, which suggesting that the stock is 412.272% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Soleno Therapeutics, Inc.'s net income of $26M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 20.98x versus 38.27x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -77.29%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat AVITA Medical, Inc.'s return on equity of -1112.54%.

Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 164.22%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $7.08 which suggests that it could grow by 59.35%. Given that Soleno Therapeutics, Inc. has higher upside potential than AVITA Medical, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than AVITA Medical, Inc..

Soleno Therapeutics, Inc. has a beta of -3.123, which suggesting that the stock is 412.272% less volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.703, suggesting its more volatile than the S&P 500 by 70.331%.

Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.

Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than AVITA Medical, Inc. quarterly revenues of $17.1M. Soleno Therapeutics, Inc.'s net income of $26M is higher than AVITA Medical, Inc.'s net income of -$13.2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 20.98x versus 1.64x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of 40.17%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 164.22%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 39.61%. Given that Soleno Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Soleno Therapeutics, Inc. has a beta of -3.123, which suggesting that the stock is 412.272% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.007%.

Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Soleno Therapeutics, Inc.'s net income of $26M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 20.98x versus 2.41x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.